596 related articles for article (PubMed ID: 25850661)
1. Islet α cells and glucagon--critical regulators of energy homeostasis.
Campbell JE; Drucker DJ
Nat Rev Endocrinol; 2015 Jun; 11(6):329-38. PubMed ID: 25850661
[TBL] [Abstract][Full Text] [Related]
2. Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
Bagger JI; Knop FK; Holst JJ; Vilsbøll T
Diabetes Obes Metab; 2011 Nov; 13(11):965-71. PubMed ID: 21615669
[TBL] [Abstract][Full Text] [Related]
3. The role of dysregulated glucagon secretion in type 2 diabetes.
D'Alessio D
Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
[TBL] [Abstract][Full Text] [Related]
4. The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror.
Martínez MS; Manzano A; Olivar LC; Nava M; Salazar J; D'Marco L; Ortiz R; Chacín M; Guerrero-Wyss M; Cabrera de Bravo M; Cano C; Bermúdez V; Angarita L
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502413
[TBL] [Abstract][Full Text] [Related]
5. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
6. Nutrient regulation of glucagon secretion: involvement in metabolism and diabetes.
Marroquí L; Alonso-Magdalena P; Merino B; Fuentes E; Nadal A; Quesada I
Nutr Res Rev; 2014 Jun; 27(1):48-62. PubMed ID: 24721112
[TBL] [Abstract][Full Text] [Related]
7. Growth factor signalling in the regulation of α-cell fate.
Kawamori D; Akiyama M; Hu J; Hambro B; Kulkarni RN
Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():21-30. PubMed ID: 21824253
[TBL] [Abstract][Full Text] [Related]
8. Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency.
Farhy LS; McCall AL
Diabetes Obes Metab; 2011 Oct; 13 Suppl 1(0 1):133-43. PubMed ID: 21824267
[TBL] [Abstract][Full Text] [Related]
9. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare KJ
Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
[TBL] [Abstract][Full Text] [Related]
10. The physiology of glucagon.
Taborsky GJ
J Diabetes Sci Technol; 2010 Nov; 4(6):1338-44. PubMed ID: 21129328
[TBL] [Abstract][Full Text] [Related]
11. Changes in obestatin gene and GPR39 receptor expression in peripheral tissues of rat models of obesity, type 1 and type 2 diabetes.
Kolodziejski PA; Pruszynska-Oszmalek E; Sassek M; Kaczmarek P; Szczepankiewicz D; Billert M; Mackowiak P; Strowski MZ; Nowak KW
J Diabetes; 2017 Apr; 9(4):353-361. PubMed ID: 27106635
[TBL] [Abstract][Full Text] [Related]
12. Islet cell function: alpha and beta cells--partners towards normoglycaemia.
Göke B
Int J Clin Pract Suppl; 2008 Mar; (159):2-7. PubMed ID: 18269435
[TBL] [Abstract][Full Text] [Related]
13. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes.
Quesada I; Tudurí E; Ripoll C; Nadal A
J Endocrinol; 2008 Oct; 199(1):5-19. PubMed ID: 18669612
[TBL] [Abstract][Full Text] [Related]
14. The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes.
Gilon P
J Mol Biol; 2020 Mar; 432(5):1367-1394. PubMed ID: 31954131
[TBL] [Abstract][Full Text] [Related]
15. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease.
Sandoval DA; D'Alessio DA
Physiol Rev; 2015 Apr; 95(2):513-48. PubMed ID: 25834231
[TBL] [Abstract][Full Text] [Related]
16. Glucagon: the effects of its excess and deficiency on insulin action.
Fanelli CG; Porcellati F; Rossetti P; Bolli GB
Nutr Metab Cardiovasc Dis; 2006 Mar; 16 Suppl 1():S28-34. PubMed ID: 16530126
[TBL] [Abstract][Full Text] [Related]
17. Paracrinology of islets and the paracrinopathy of diabetes.
Unger RH; Orci L
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16009-12. PubMed ID: 20798346
[TBL] [Abstract][Full Text] [Related]
18. Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes.
Reiband HK; Schmidt S; Ranjan A; Holst JJ; Madsbad S; Nørgaard K
Diabetes Metab Res Rev; 2015 Oct; 31(7):672-9. PubMed ID: 25533565
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibition and glucagon secretion in humans.
Saponaro C; Pattou F; Bonner C
Diabetes Metab; 2018 Nov; 44(5):383-385. PubMed ID: 30017776
[TBL] [Abstract][Full Text] [Related]
20. The role of intramyocellular lipids during hypoglycemia in patients with intensively treated type 1 diabetes.
Bernroider E; Brehm A; Krssak M; Anderwald C; Trajanoski Z; Cline G; Shulman GI; Roden M
J Clin Endocrinol Metab; 2005 Oct; 90(10):5559-65. PubMed ID: 15998784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
